NO20063368L - Alfa-aminoamid-derivater anvendelige ved behandling av lidelser i nedre urinveier - Google Patents
Alfa-aminoamid-derivater anvendelige ved behandling av lidelser i nedre urinveierInfo
- Publication number
- NO20063368L NO20063368L NO20063368A NO20063368A NO20063368L NO 20063368 L NO20063368 L NO 20063368L NO 20063368 A NO20063368 A NO 20063368A NO 20063368 A NO20063368 A NO 20063368A NO 20063368 L NO20063368 L NO 20063368L
- Authority
- NO
- Norway
- Prior art keywords
- urinary tract
- lower urinary
- tract disorders
- alpha
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/28—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/58—Radicals substituted by nitrogen atoms
Abstract
Fremgangsmåter for anvendelse av visse a-aminoamidderivater for å behandle forstyrrelser i nedre urinveissystem. De terapeutiske midlene ifølge oppfinnelsen er i stand til å redusere eller til og med stanse de nedre urinveisforstyrrelsene vesentlig uten bivirkninger.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04001175A EP1557166A1 (en) | 2004-01-21 | 2004-01-21 | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders |
PCT/EP2005/000514 WO2005070405A1 (en) | 2004-01-21 | 2005-01-20 | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20063368L true NO20063368L (no) | 2006-10-12 |
Family
ID=34626470
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20063368A NO20063368L (no) | 2004-01-21 | 2006-07-20 | Alfa-aminoamid-derivater anvendelige ved behandling av lidelser i nedre urinveier |
Country Status (15)
Country | Link |
---|---|
US (1) | US7718815B2 (no) |
EP (1) | EP1557166A1 (no) |
JP (1) | JP2007518763A (no) |
KR (1) | KR101310882B1 (no) |
CN (1) | CN100584323C (no) |
AU (1) | AU2005205903B2 (no) |
BR (1) | BRPI0506970B8 (no) |
CA (1) | CA2554047A1 (no) |
HK (1) | HK1103282A1 (no) |
IL (1) | IL176968A (no) |
NO (1) | NO20063368L (no) |
NZ (1) | NZ548638A (no) |
PL (1) | PL380825A1 (no) |
RU (1) | RU2395504C2 (no) |
WO (1) | WO2005070405A1 (no) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2363983A (en) * | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 7-hydroxyepiandrosterone |
CN101018546B (zh) * | 2004-09-10 | 2013-06-12 | 纽朗制药有限公司 | 作为钠和/或钙通道选择性调节剂的(卤代苄氧基)苄氨基-丙酰胺类 |
MY144968A (en) | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
AR053710A1 (es) | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
WO2007002885A2 (en) * | 2005-06-29 | 2007-01-04 | University Of Virginia Patent Foundation | Compositions and methods for use of a sodium channel blocker |
BRPI0620239B8 (pt) * | 2005-12-22 | 2021-05-25 | Newron Pharm Spa | derivados de 2-feniletilamino. |
AU2007263328C1 (en) | 2006-06-19 | 2012-09-06 | Newron Pharmaceuticals S.P.A. | Process for the production of 2- [4 - ( 3- and 2-fluorobenzyloxy) benzylamino] propan amides |
WO2008046087A2 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiro compounds and their uses as therapeutic agents |
EP2073806B1 (en) | 2006-10-12 | 2012-02-15 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
LT2155663T (lt) | 2007-06-15 | 2018-02-12 | Newron Pharmaceuticals S.P.A. | Pakeisti 2-[2-(fenil)etilamino]alkanamidų dariniai ir jų, kaip natrio ir (arba) kalcio kanalų moduliatorių, panaudojimas |
EP2229351B1 (en) | 2007-12-11 | 2017-11-08 | Newron Pharmaceuticals S.p.A. | Process for the production of 2-[4-(3- or 2-fluorobenzyloxy)benzylamino]propanamides with high purity degree |
EP2350090B1 (en) | 2008-10-17 | 2015-06-03 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
EP2350091B1 (en) | 2008-10-17 | 2015-06-03 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
MY179342A (en) | 2009-10-14 | 2020-11-04 | Xenon Pharmaceuticals Inc | Synthetic methods for spiro-oxindole compounds |
WO2011106729A2 (en) | 2010-02-26 | 2011-09-01 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
HUE030504T2 (en) | 2010-04-27 | 2017-05-29 | Newron Pharm Spa | Process for the preparation of ralfinamide methanesulfonate salts or their R-enantiomers |
AR103636A1 (es) | 2015-02-05 | 2017-05-24 | Teva Pharmaceuticals Int Gmbh | Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL94466A (en) * | 1989-05-25 | 1995-01-24 | Erba Carlo Spa | Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation |
GB9515412D0 (en) * | 1995-07-27 | 1995-09-27 | Pharmacia Spa | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives |
IL136044A (en) * | 1997-11-21 | 2005-08-31 | Euro Celtique Sa | 2-aminoacetamide derivatives and pharmaceutical compositions containing the same |
GB9727523D0 (en) * | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
ES2253579T3 (es) * | 2001-09-03 | 2006-06-01 | Newron Pharmaceuticals S.P.A. | Composicion farmaceutica que comprende gabapentina o un analogo suyo y una alfa-aminoamida y su uso analgesico. |
WO2004066990A2 (en) | 2003-01-30 | 2004-08-12 | Dynogen Pharmaceuticals, Inc. | Methods of treating lower urinary tract disorders using sodium channel modulators |
AU2004266494B2 (en) | 2003-08-25 | 2010-04-08 | Newron Pharmaceuticals, Spa | Alpha-aminoamide derivatives useful as anti-inflammatory agents |
-
2004
- 2004-01-21 EP EP04001175A patent/EP1557166A1/en not_active Withdrawn
-
2005
- 2005-01-20 AU AU2005205903A patent/AU2005205903B2/en active Active
- 2005-01-20 KR KR1020067014655A patent/KR101310882B1/ko active IP Right Grant
- 2005-01-20 US US10/586,494 patent/US7718815B2/en active Active
- 2005-01-20 CA CA002554047A patent/CA2554047A1/en not_active Abandoned
- 2005-01-20 JP JP2006550030A patent/JP2007518763A/ja active Pending
- 2005-01-20 CN CN200580002785A patent/CN100584323C/zh active Active
- 2005-01-20 WO PCT/EP2005/000514 patent/WO2005070405A1/en active Application Filing
- 2005-01-20 PL PL380825A patent/PL380825A1/pl not_active Application Discontinuation
- 2005-01-20 NZ NZ548638A patent/NZ548638A/en unknown
- 2005-01-20 RU RU2006126346/04A patent/RU2395504C2/ru active
- 2005-01-20 BR BRPI0506970A patent/BRPI0506970B8/pt active IP Right Grant
-
2006
- 2006-07-20 IL IL176968A patent/IL176968A/en active IP Right Grant
- 2006-07-20 NO NO20063368A patent/NO20063368L/no not_active Application Discontinuation
-
2007
- 2007-07-09 HK HK07107315.6A patent/HK1103282A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
IL176968A0 (en) | 2006-12-10 |
BRPI0506970B8 (pt) | 2021-05-25 |
EP1557166A1 (en) | 2005-07-27 |
CN100584323C (zh) | 2010-01-27 |
HK1103282A1 (en) | 2007-12-14 |
US7718815B2 (en) | 2010-05-18 |
BRPI0506970A (pt) | 2007-07-03 |
RU2006126346A (ru) | 2008-01-27 |
US20080132567A1 (en) | 2008-06-05 |
NZ548638A (en) | 2010-02-26 |
RU2395504C2 (ru) | 2010-07-27 |
PL380825A1 (pl) | 2007-03-19 |
KR20070007776A (ko) | 2007-01-16 |
WO2005070405A1 (en) | 2005-08-04 |
JP2007518763A (ja) | 2007-07-12 |
CN1956714A (zh) | 2007-05-02 |
AU2005205903B2 (en) | 2010-04-29 |
IL176968A (en) | 2012-10-31 |
AU2005205903A1 (en) | 2005-08-04 |
BRPI0506970B1 (pt) | 2019-08-13 |
KR101310882B1 (ko) | 2013-09-25 |
CA2554047A1 (en) | 2005-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20063368L (no) | Alfa-aminoamid-derivater anvendelige ved behandling av lidelser i nedre urinveier | |
EP2286839A3 (en) | Treatment of obesity and related diseases | |
NO20064732L (no) | Alfa-aminoamidderivater nyttige i behandlingen av urolige bein-syndromet og additive lidelser | |
NO20070049L (no) | Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese | |
PL1919466T3 (pl) | Formulacje do leczenia nieprawidłowości lipoproteinowych obejmujące statynę i pochodną metylonikotynoamidu | |
BRPI0514017A (pt) | indazóis úteis no tratamento de doenças cardiovasculares | |
NO20081842L (no) | Fremgangsmåter og sammensetninger for anvendelse ved behandling av pasienter med autoantistoff-positive sykdommer | |
NO20092637L (no) | Fremgangsmater for behandling | |
MY148985A (en) | 2-aminopyridine analogs as glucokinase activators | |
NO20072665L (no) | Rapamycinderivater og deres anvendelse i behandling av nevrologiske lidelser | |
WO2006074265A3 (en) | Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders | |
TN2010000214A1 (en) | Methods for treating obesity and obesity related diseases and disorders | |
NO20055563L (no) | Midler for behandlingen av lavere abdominale lidelser | |
DE602006017574D1 (de) | Als protein-kinase-inhibitoren nutzbare benzimidazole | |
WO2006086693A3 (en) | Medical devices | |
MX2007010484A (es) | Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2. | |
WO2007055743A3 (en) | Treatment of obesity and related disorders | |
WO2006135694A3 (en) | Uii-modulating compounds and their use | |
EA200901062A1 (ru) | Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств | |
WO2006109170A3 (en) | Combination therapy for treatment of cardiovascular diseases and related conditions | |
NO20073610L (no) | Nye substituerte tiofenpyrimidinonderivater som inhibitorer for 17 β-hydroksysteroiddehydrogenase | |
EA200801940A1 (ru) | Применение стробилуринов для лечения нарушений метаболизма железа | |
WO2007128088A3 (en) | Use of n-aminoimidazole cytoprotective compounds for treating cell death and/or gsk-3 mediated diseases | |
WO2008057543A3 (en) | Uii-modulating compounds and their use | |
WO2006060203A3 (en) | Imidazole derivatives for the treatment of dementia and related disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |